An interventional study of Bilberry and Placebo in Myocardial Infarction, sponsored by Ole Frobert, MD, PhD. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Ole Frobert, MD, PhD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Myocardial Infarction with a site in Sweden — 13 open to participants now, 22 under way, 4 of them phase 3. Myocardial Infarction · Sweden.
Among the 90 studies in Myocardial Infarction with a site in Sweden, this one is the 34th largest by planned enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2021, is one of 23 with no phase, reaches primary completion later than 9 of the 21 other live ones, and was the 58th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →13 of the 90 studies in Myocardial Infarction with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18–55
Abcentra · Sites in Sweden, United States, Czechia and 6 more countries
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 18+ · Healthy volunteers
Karolinska Institutet · Sites in Sweden
Ages 18+
Uppsala University · Sites in Sweden
Ages 50–80
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 26 · Phase 4 11
First in 1997; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 900 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 875 across the 70 interventional studies, 5,518 across the 20 observational. Of the 64 that completed or were terminated, 21 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 90 have an industry lead sponsor. The 10 most frequent:
Ole Frobert, MD, PhD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Ole Frobert, MD, PhD has 2 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
6 of the studies in Myocardial Infarction with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05889416Skane University HospitalThe Perfect-CR Implementation Study | 2026-12 |
| NCT03620266Ole Frobert, MD, PhDEffects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI | 2026-12-31 |
| NCT07706816Uppsala UniversityEvaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study | 2027-01-31 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 90 studies in Myocardial Infarction with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Bilberries from Sweden, rich in polyphenols, have shown cholesterol-lowering effects in small studies, and the cholesterol-lowering properties of oats, with abundant beta-glucans and potentially bioactive phytochemicals, are well established. Both may provide cardiometabolic benefits for patients with manifest chronic cardiometabolic disease, such as type 2 diabets mellitus (T2DM) and myocardial infarction (MI). However, large studies of adequate statistical power and appropriate duration are needed to confirm clinically relevant treatment effects. No previous study has evaluated the potential additive or synergistic effects of bilberry combined with oats on cardiometabolic risk factors.
Design:
This is a double-blind, randomized, placebo-controlled clinical trial. Our primary objective is to assess cardioprotective effects of diet supplementation with dried bilberry and with bioprocessed oat bran, with a secondary explorative objective of assessing their combination, compared with a neutral isocaloric reference supplement, for patients diagnosed with T2DM and/or MI. Patients will be randomized 1:1:1:1 to a three-month intervention. The primary endpoint is the difference in LDL cholesterol change between the intervention groups after three months. The major secondary endpoint is exercise capacity at three months. Other secondary endpoints include plasma concentrations of biochemical markers of inflammation, glycaemia, and gut microbiota composition after three months.
Implications:
Secondary prevention after cardiometabolic disease, including T2DM and MI, has improved during the last decades but diabetes complications, readmissions and cadiovascular related deaths following these conditions remain large health care challenges. Controlling hyperlipidemia, hyperglycaemia, hypertension and inflammation is critical to preventing (new) cardiovascular events, but novel pharmacological treatments for these conditions are expensive and associated with negative side effects. If bilberry and/or oat, in addition to standard medical therapy, can lower LDL cholesterol and inflammation more than standard therapy alone, this could be a cost-effective and safe dietary strategy for secondary prevention in high-risk patients or risk prevention in subjects with T2DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
Dietary Supplement: Bilberry
Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
Dietary Supplement: Placebo
Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
Dietary Supplement: Bioprocessed oat bran
Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
Dietary Supplement: Combination bilberry/oats
The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
Plasma levels of LDL cholesterol
The effect of intervention on difference between the groups of LDL cholesterol after three months
Time frame: Three months
Plasma lipid profile
The effect of intervention on differences between the groups of fasting lipid profile including HDL, triglycerides, total cholesterol, small-dense LDL cholesterol, apo A, apo B, Lp(a) and oxidized LDL.
Time frame: Three months
Symptom-limited bicycle ergometer test
The effect of intervention on exercise capacity (measured as maximal workload in Watts and as estimated maximal oxygen uptake (VO2 max))
Time frame: Three months
Dynamic unilateral heel-lft and unilateral shoulder flexion tests
The effect of intervention on muscle endurance
Time frame: Three months
Self-reported physical activity level
The effect of intervention on the Frändin/Grimby activity scale (6 levels of physical activity, min:1 (low activity) max:6 (heavy activity)) and the Haskell physical activity scale ("For how many days were you physically active during the last week for at least 20 minutes?", min:0 max:7)
Time frame: Three months
Plasma Cardiac Troponin Concentration
Change in plasma cardiac troponin (high-sensitivity cardiac troponin T or I) concentration from baseline to 3 months to assess myocardial injury. The effect of intervention on Troponin levels, Unit of Measure: ng/L
Time frame: Three months
Plasma NT-proBNP Concentration
Change in plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline to 3 months to assess cardiac stress, pg/mL
Time frame: Three months
Plasma hs-CRP Concentration
Change in plasma high-sensitivity C-reactive protein (hs-CRP) concentration from baseline to 3 months to assess systemic inflammation. Unit of Measure: mg/L
Time frame: Three months
Plasma IL-6 Concentration
Change in plasma interleukin-6 (IL-6) concentration from baseline to 3 months to assess inflammatory response. Unit of Measure: pg/mL
Time frame: Three months
Glycosylated Hemoglobin (HbA1c)
Change in glycosylated hemoglobin (HbA1c) from baseline to 3 months to assess glycemic control. Unit of Measure: %
Time frame: Three months
Fasting Plasma Insulin Concentration
Change in fasting plasma insulin concentration from baseline to 3 months to assess insulin sensitivity and metabolic status. Unit of Measure: µIU/mL (micro-international units per milliliter)
Time frame: Three months
Fasting Plasma C-Peptide Concentration
Change in fasting plasma C-peptide concentration from baseline to 3 months to assess endogenous insulin secretion and beta-cell function. Unit of Measure: ng/mL
Time frame: Three months
Serum Creatinine Concentration
Change in serum creatinine concentration from baseline to 3 months to assess renal function. Unit of Measure: mg/dL
Time frame: Three months
Fasting Plasma Glucose Concentration
Change in fasting plasma glucose concentration from baseline to 3 months to assess glycemic control. Unit of Measure: mg/dL Unit of Measure: mg/dL
Time frame: Three months
Serum Cystatin C Concentration
Change in serum cystatin C concentration from baseline to 3 months to assess renal function and estimate glomerular filtration independent of muscle mass. Unit of Measure: mg/L Unit of Measure: mg/dL Unit of Measure: mg/dL
Time frame: Three months
Untargeted plasma metabolome
Untargeted plasma metabolomics will be employed to exploratively assess alterations in endogenous and exposome-related metabolites and to identify metabolites that may differ with treatment.
Time frame: Three months
Fecal samples of gut microbiota composition
These exploratory analyses of will allow to investigate the extent to which gut microbiota composition and activity differs between responders and non-responders to the interventions.
Time frame: Three months
Left ventricular systolic function
The effect of intervention on left ventricular function. Baseline left ventricular systolic function, expressed as global ejection fraction in percent according to the biplane Simpson method, will be evaluated by echocardiography by the discharging physician. The procedure will be repeated after three months by an experienced echocardiography technician blinded to results of the initial examinations
Time frame: Three months
Resting heart rate
The effect of intervention on resting heart rate
Time frame: Three months
Systolic and diastolic blood pressure
The effect of intervention on blood pressure (mmHg)
Time frame: Three months
Urine albumin-creatinine ratio
Urine albumin-creatinine ratio will be measured for for T2DM only
Time frame: Three months
Continuous glucose monitoring with Continuous Glucose Monitors (CGM) - FreeStyle model 2
Continuous glucose monitoring (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Body composition with multi-frequency bioimpedance
The effect of intervention on body composition measured with multi-frequency bioimpedance (for T2DM only)
Time frame: Three months
Diabetic retinal changes
The effect of intervention on diabetic retinal changes (eye fundus examination) (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Platelet aggregation (Primary hemostasis)
Ex vivo platelet aggregation in whole blood measured with impedance aggregometry (Multiplate®, Roche, Switzerland) after stimulation with adenosine diphosphate (ADP), arachidonic acid and thrombin-related activation peptide (TRAP-6). Unit of measure: Aggregation units x min. (in a subset of T2DM only, n=100 in total)
Time frame: Three months
P-selectin levels (Primary hemostasis)
Plasma concentration of P-selectin measured with commercial ELISA (CD62P Quantikine, Biotechne, Dublin, Ireland). Unit of measure: ng/mL. (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Ex vivo thrombin generation (Secondary hemostasis)
Ex vivo thrombin generation (endogenous thrombin potential) in platelet-poor plasma measured using Calibrated Automated Thrombogram (BV Thrombinoscope, Maastricht, the Netherlands) after stimulation with tissue factor. Unit of measure: nM x min. (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Prothrombin fragment 1+2 (Secondary hemostasis)
Plasma concentration of prothrombin fragment 1+2, measured with commercial ELISA (EnzygnostTM, Siemens Healthineers, Ballerup, Denmark). Unit of measure: pmol/L. (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Fibrinolysis speed
Ex vivo fibrinolytic capacity (fibrinolysis speed) in whole blood measured with in-house modified rotational thromboelastometry after stimulation with tissue factor and tissue plasminogen activator. Unit of measure: mm/min. (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Fibrinolytic capacity
Ex vivo fibrinolytic capacity (time from peak fibrin to 50% lysis) in platelet-poor plasma measured with in-house turbidimetric fibrin formation and lysis assay. Unit of measure: seconds. (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Fibrinolytic markers
Plasma concentrations of plasminogen activity, tissue plasminogen activator (unit of measure: ng/mL) and plasminogen activator inhibitor-1 (unit of measure: ng/mL) measured with ELISA (Technozym®, Technoclone, Vienna, Austria). (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Endothelial activation
Plasma concentrations of syndecan-1 (unit of measure: ng/mL) and thrombomodulin (unit of measure: ng/mL) measured with commercial ELISA kits (CD138 kit and CD141 kit, Diaclone, Medix Biochemica, Espoo, Finland). (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Inflammation
The effect of intervention on inflammatory markers (Olink panel) (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Oxidative stress
The effect of intervention on 8-Oxo-2'-deoxyguanosine levels (in a subset of T2DM only, n=100 in total)
Time frame: Three months
Plan to share: No
Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 63 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vaccinium myrtillus extract